Fat-specific DsbA-L overexpression promotes adiponectin multimerization and protects mice from diet-induced obesity and insulin resistance

Meilian Liu, Ruihua Xiang, Sarah Ann Wilk, Ning Zhang, Lauren B. Sloane, Kian Azarnoush, Lijun Zhou, Hongzhi Chen, Guangda Xiang, Christi A. Walter, Steven N. Austad, Nicolas Musi, Ralph A. DeFronzo, Reto Asmis, Philipp E. Scherer, Lily Q. Dong, Feng Liu

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The antidiabetic and antiatherosclerotic effects of adiponectin make it a desirable drug target for the treatment of metabolic and cardiovascular diseases. However, the adiponectin-based drug development approach turns out to be difficult due to extremely high serum levels of this adipokine. On the other hand, a significant correlation between adiponectin multimerization and its insulin-sensitizing effects has been demonstrated, suggesting a promising alternative therapeutic strategy. Here we show that transgenic mice overexpressing disulfide bond A oxidoreductase-like protein in fat (fDsbA-L) exhibited increased levels of total and the high-molecular-weight form of adiponectin compared with wild-type (WT) littermates. The fDsbA-L mice also displayed resistance to diet-induced obesity, insulin resistance, and hepatic steatosis compared with WT control mice. The protective effects of DsbA-L overexpression on diet-induced insulin resistance, but not increased body weight and fat cell size, were significantly decreased in adiponectin-deficient fDsbA-L mice (fDsbA-L/Ad-/-). In addition, the fDsbA-L/Ad -/- mice displayed greater activity and energy expenditure compared with adiponectin knockout mice under a high-fat diet. Taken together, our results demonstrate that DsbA-L protects mice from diet-induced obesity and insulin resistance through adiponectin-dependent and independent mechanisms. In addition, upregulation of DsbA-L could be an effective therapeutic approach for the treatment of obesity and its associated metabolic disorders.

Original languageEnglish (US)
Pages (from-to)2776-2786
Number of pages11
JournalDiabetes
Volume61
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Adiponectin
Insulin Resistance
Obesity
Fats
Diet
Adipokines
Metabolic Diseases
High Fat Diet
Cell Size
Hypoglycemic Agents
Adipocytes
Knockout Mice
Disulfides
Pharmaceutical Preparations
Energy Metabolism
Transgenic Mice
Adipose Tissue
Oxidoreductases
Cardiovascular Diseases
Up-Regulation

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Fat-specific DsbA-L overexpression promotes adiponectin multimerization and protects mice from diet-induced obesity and insulin resistance. / Liu, Meilian; Xiang, Ruihua; Wilk, Sarah Ann; Zhang, Ning; Sloane, Lauren B.; Azarnoush, Kian; Zhou, Lijun; Chen, Hongzhi; Xiang, Guangda; Walter, Christi A.; Austad, Steven N.; Musi, Nicolas; DeFronzo, Ralph A.; Asmis, Reto; Scherer, Philipp E.; Dong, Lily Q.; Liu, Feng.

In: Diabetes, Vol. 61, No. 11, 11.2012, p. 2776-2786.

Research output: Contribution to journalArticle

Liu, M, Xiang, R, Wilk, SA, Zhang, N, Sloane, LB, Azarnoush, K, Zhou, L, Chen, H, Xiang, G, Walter, CA, Austad, SN, Musi, N, DeFronzo, RA, Asmis, R, Scherer, PE, Dong, LQ & Liu, F 2012, 'Fat-specific DsbA-L overexpression promotes adiponectin multimerization and protects mice from diet-induced obesity and insulin resistance', Diabetes, vol. 61, no. 11, pp. 2776-2786. https://doi.org/10.2337/db12-0169
Liu, Meilian ; Xiang, Ruihua ; Wilk, Sarah Ann ; Zhang, Ning ; Sloane, Lauren B. ; Azarnoush, Kian ; Zhou, Lijun ; Chen, Hongzhi ; Xiang, Guangda ; Walter, Christi A. ; Austad, Steven N. ; Musi, Nicolas ; DeFronzo, Ralph A. ; Asmis, Reto ; Scherer, Philipp E. ; Dong, Lily Q. ; Liu, Feng. / Fat-specific DsbA-L overexpression promotes adiponectin multimerization and protects mice from diet-induced obesity and insulin resistance. In: Diabetes. 2012 ; Vol. 61, No. 11. pp. 2776-2786.
@article{128d4aa2257d4ed58f4796a2a4f5463f,
title = "Fat-specific DsbA-L overexpression promotes adiponectin multimerization and protects mice from diet-induced obesity and insulin resistance",
abstract = "The antidiabetic and antiatherosclerotic effects of adiponectin make it a desirable drug target for the treatment of metabolic and cardiovascular diseases. However, the adiponectin-based drug development approach turns out to be difficult due to extremely high serum levels of this adipokine. On the other hand, a significant correlation between adiponectin multimerization and its insulin-sensitizing effects has been demonstrated, suggesting a promising alternative therapeutic strategy. Here we show that transgenic mice overexpressing disulfide bond A oxidoreductase-like protein in fat (fDsbA-L) exhibited increased levels of total and the high-molecular-weight form of adiponectin compared with wild-type (WT) littermates. The fDsbA-L mice also displayed resistance to diet-induced obesity, insulin resistance, and hepatic steatosis compared with WT control mice. The protective effects of DsbA-L overexpression on diet-induced insulin resistance, but not increased body weight and fat cell size, were significantly decreased in adiponectin-deficient fDsbA-L mice (fDsbA-L/Ad-/-). In addition, the fDsbA-L/Ad -/- mice displayed greater activity and energy expenditure compared with adiponectin knockout mice under a high-fat diet. Taken together, our results demonstrate that DsbA-L protects mice from diet-induced obesity and insulin resistance through adiponectin-dependent and independent mechanisms. In addition, upregulation of DsbA-L could be an effective therapeutic approach for the treatment of obesity and its associated metabolic disorders.",
author = "Meilian Liu and Ruihua Xiang and Wilk, {Sarah Ann} and Ning Zhang and Sloane, {Lauren B.} and Kian Azarnoush and Lijun Zhou and Hongzhi Chen and Guangda Xiang and Walter, {Christi A.} and Austad, {Steven N.} and Nicolas Musi and DeFronzo, {Ralph A.} and Reto Asmis and Scherer, {Philipp E.} and Dong, {Lily Q.} and Feng Liu",
year = "2012",
month = "11",
doi = "10.2337/db12-0169",
language = "English (US)",
volume = "61",
pages = "2776--2786",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Fat-specific DsbA-L overexpression promotes adiponectin multimerization and protects mice from diet-induced obesity and insulin resistance

AU - Liu, Meilian

AU - Xiang, Ruihua

AU - Wilk, Sarah Ann

AU - Zhang, Ning

AU - Sloane, Lauren B.

AU - Azarnoush, Kian

AU - Zhou, Lijun

AU - Chen, Hongzhi

AU - Xiang, Guangda

AU - Walter, Christi A.

AU - Austad, Steven N.

AU - Musi, Nicolas

AU - DeFronzo, Ralph A.

AU - Asmis, Reto

AU - Scherer, Philipp E.

AU - Dong, Lily Q.

AU - Liu, Feng

PY - 2012/11

Y1 - 2012/11

N2 - The antidiabetic and antiatherosclerotic effects of adiponectin make it a desirable drug target for the treatment of metabolic and cardiovascular diseases. However, the adiponectin-based drug development approach turns out to be difficult due to extremely high serum levels of this adipokine. On the other hand, a significant correlation between adiponectin multimerization and its insulin-sensitizing effects has been demonstrated, suggesting a promising alternative therapeutic strategy. Here we show that transgenic mice overexpressing disulfide bond A oxidoreductase-like protein in fat (fDsbA-L) exhibited increased levels of total and the high-molecular-weight form of adiponectin compared with wild-type (WT) littermates. The fDsbA-L mice also displayed resistance to diet-induced obesity, insulin resistance, and hepatic steatosis compared with WT control mice. The protective effects of DsbA-L overexpression on diet-induced insulin resistance, but not increased body weight and fat cell size, were significantly decreased in adiponectin-deficient fDsbA-L mice (fDsbA-L/Ad-/-). In addition, the fDsbA-L/Ad -/- mice displayed greater activity and energy expenditure compared with adiponectin knockout mice under a high-fat diet. Taken together, our results demonstrate that DsbA-L protects mice from diet-induced obesity and insulin resistance through adiponectin-dependent and independent mechanisms. In addition, upregulation of DsbA-L could be an effective therapeutic approach for the treatment of obesity and its associated metabolic disorders.

AB - The antidiabetic and antiatherosclerotic effects of adiponectin make it a desirable drug target for the treatment of metabolic and cardiovascular diseases. However, the adiponectin-based drug development approach turns out to be difficult due to extremely high serum levels of this adipokine. On the other hand, a significant correlation between adiponectin multimerization and its insulin-sensitizing effects has been demonstrated, suggesting a promising alternative therapeutic strategy. Here we show that transgenic mice overexpressing disulfide bond A oxidoreductase-like protein in fat (fDsbA-L) exhibited increased levels of total and the high-molecular-weight form of adiponectin compared with wild-type (WT) littermates. The fDsbA-L mice also displayed resistance to diet-induced obesity, insulin resistance, and hepatic steatosis compared with WT control mice. The protective effects of DsbA-L overexpression on diet-induced insulin resistance, but not increased body weight and fat cell size, were significantly decreased in adiponectin-deficient fDsbA-L mice (fDsbA-L/Ad-/-). In addition, the fDsbA-L/Ad -/- mice displayed greater activity and energy expenditure compared with adiponectin knockout mice under a high-fat diet. Taken together, our results demonstrate that DsbA-L protects mice from diet-induced obesity and insulin resistance through adiponectin-dependent and independent mechanisms. In addition, upregulation of DsbA-L could be an effective therapeutic approach for the treatment of obesity and its associated metabolic disorders.

UR - http://www.scopus.com/inward/record.url?scp=84868008250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868008250&partnerID=8YFLogxK

U2 - 10.2337/db12-0169

DO - 10.2337/db12-0169

M3 - Article

VL - 61

SP - 2776

EP - 2786

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 11

ER -